NCT00753545 2025-02-03
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
AstraZeneca
Phase 2 Completed
Clinical Trials
11 trialsNCT00516373 2024-02-22
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
AstraZeneca
Phase 1 Completed
NCT00494234 2024-01-19
ICEBERG 1
AstraZeneca
Phase 2 Completed
NCT02039388 2022-09-02
LUSTIC
Medical University of Vienna
Phase NA Completed
NCT00001806 2019-12-12
Methods in Education for Breast Cancer Genetics
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00628251 2019-12-05
ICEBERG 3
AstraZeneca
Phase 2 Completed
NCT02418624 2019-01-16
REVIVAL
The Netherlands Cancer Institute
Phase 1 Completed
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed
NCT01339650 2018-01-02
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AbbVie
Phase 1 Completed
NCT00419510 2016-08-17
Genetic Counseling in African American Women
University of Pennsylvania
Phase NA Completed
NCT00165152 2012-08-09
Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing
Dana-Farber Cancer Institute
Phase NA Completed